<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human leukocyte antigen G (HLA-G) molecules exhibit immunomodulatory properties corresponding to nonclassic class I genes of the major histocompatibility complex </plain></SENT>
<SENT sid="1" pm="."><plain>They are either membrane-bound or solubly expressed during certain tumoral <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Soluble human leukocyte antigen G (sHLA-G) molecules seem more frequently expressed than membrane-bound isoforms during <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, such as <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Assay of these molecules by enzyme-linked immunosorbent assay in patients suffering from another <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorder</z:e> (<z:hpo ids='HP_0002488'>acute leukemia</z:hpo>) highlights increased sHLA-G secretion </plain></SENT>
<SENT sid="4" pm="."><plain>This increased secretion seems more marked in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> subtypes affecting monocytic and lymphoid lineages such as <z:e sem="disease" ids="C0023479" disease_type="Neoplastic Process" abbrv="AMML">FABM4</z:e> and <z:e sem="disease" ids="C0023465" disease_type="Neoplastic Process" abbrv="">FABM5</z:e>, as well as both B and T <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, this study uses in vitro cytokine stimulations and reveals the respective potential roles of granulocyte-macrophage colony-stimulating factor and interferon-gamma in increasing this secretion in <z:e sem="disease" ids="C0023479" disease_type="Neoplastic Process" abbrv="AMML">FABM4</z:e> and ALL </plain></SENT>
<SENT sid="6" pm="."><plain>Correlations between sHLA-G plasma level and clinical biologic features suggest a link between elevated sHLA-G level and 1) the absence of anterior <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> and 2) high-level <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> these findings suggest that sHLA-G molecules could be a factor in tumoral escape from immune survey during <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
</text></document>